Actively Recruiting
Tracking Minimal Residual Disease Using Blood Tests in Breast Cancer Patients Long-Term Observation of ctDNA Profiles Across Treatment and Surveillance Phases
Led by Tempus AI · Updated on 2026-09-03
900
Participants Needed
16
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how detecting minimal residual disease MRD through circulating tumor DNA ctDNA in the blood might help predict breast cancer recurrence and monitor treatment response. This observational research involves patients with different types of breast cancer, including triple negative, HR positiveHER2 negative, and HER2 positive, focusing on those treated with curative intent at various stages. Participants are grouped into three cohorts based on their treatment and disease status those receiving neoadjuvant therapy before surgery, those undergoing adjuvant therapy or surveillance after surgery, and those with no evidence of disease for at least five years post diagnosis. There are no study interventions instead, participants are observed and monitored over time. Throughout the study, participants provide biospecimens including blood samples for longitudinal ctDNA testing. Researchers will evaluate invasive disease-free survival, distant disease-free survival, overall survival, and other cancer burden measures over a five-year period. The study aims to improve understanding of breast cancer management by tracking cancer DNA in the blood across different treatment phases.
CONDITIONS
Brief Title
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Research Team
G
GEMINI Breast Clinical Study Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here